Immuno-Oncology
The crowd matters.
For far too long, we the people who want to give and get better care have had no say in what new ideas get into practice. When you support new ideas here they are over 20 times more likely to get out to market - sometimes incredibly fast. So explore, like, try, pilot, partner, mentor, or invest in these companies and ideas and let's fix healthcare, one awesome idea at a time!
See the companies ↓Part of Cancer & Oncology
Fyggy's top 8 in Immuno-Oncology
Ranked by MedStartr Engagement Score.
- 1MedGenomeMedStartr Engagement Score5MedStartr Engagement Score5
- 1Apricity HealthMedStartr Engagement Score5MedStartr Engagement Score5
- 1PersonalisMedStartr Engagement Score5MedStartr Engagement Score5
- 1Nilogen OncosystemsMedStartr Engagement Score5MedStartr Engagement Score5
- 1Turnstone BiologicsMedStartr Engagement Score5MedStartr Engagement Score5
- 1BioGraph 55MedStartr Engagement Score5MedStartr Engagement Score5
- 1NoetikMedStartr Engagement Score5MedStartr Engagement Score5
- 8neoX (星亢原)MedStartr Engagement Score4MedStartr Engagement Score4
Companies in Immuno-Oncology
Only accessible to MedStartr community members.
Join nowOnly accessible to MedStartr community members.
Join nowOnly accessible to MedStartr community members.
Join nowOnly accessible to MedStartr community members.
Join nowOnly accessible to MedStartr community members.
Join nowOnly accessible to MedStartr community members.
Join nowOnly accessible to MedStartr community members.
Join nowOnly accessible to MedStartr community members.
Join now
Andreessen Horowitz
San Francisco, CA, United States
Andreessen Horowitz is a venture capital firm based in San Francisco, California. The firm is associated with prominent individuals like Chris Dixon and Davide Ulevitch and coll...
...moreOnly accessible to MedStartr community members.
Join nowOnly accessible to MedStartr community members.
Join nowRelated Companies
Semantically similar companies discovered by AI
Only accessible to MedStartr community members.
Join now
OncoLens
Atlanta, Georgia, United States
A precision oncology solutions company.
Only accessible to MedStartr community members.
Join now
Only accessible to MedStartr community members.
Join now
Vivere Oncotherapies
Berkeley, California, US
Vivere Oncotherapies is a bioengineering company developing targeted gene therapies to activate the immune system against "cold" solid tumors that are resistant to existing trea...
...moreOnly accessible to MedStartr community members.
Join nowOnly accessible to MedStartr community members.
Join nowOxford BioTherapeutics
Oxford, CA, UK
Oxford BioTherapeutics (OBT) is a clinical-stage oncology company based in Oxford, UK, and San Jose, USA. It is dedicated to discovering and developing first-in-class antibody-b...
...moreOnly accessible to MedStartr community members.
Join nowOnly accessible to MedStartr community members.
Join nowKopra Bio
San Francisco, California, US
Kopra Bio is a biotechnology company developing immunotherapies for cancer, specifically for solid tumors, by using genetically engineered viruses that stimulate the immune system.
...moreOnly accessible to MedStartr community members.
Join now
Note, this image was autogenerated by Syggy based on what we know about the company. It is not an official company publication.
Only accessible to MedStartr community members.
Join now1200 Pharma
Pasadena, CA, US
A clinical-stage pharmaceutical company developing novel drug formulations for oncology indications using its proprietary MITO technology platform to target the mitochondria of ...
...moreOnly accessible to MedStartr community members.
Join now
Only accessible to MedStartr community members.
Join now
Precision Biosciences
Durham, NC, US
Precision Biosciences is a biotechnology company focused on developing gene editing therapies for cancer immunotherapy.
Only accessible to MedStartr community members.
Join nowRelated Disease Areas
Immuno-Oncology Salon
Share photos and talk with people who care about Immuno-Oncology. Please follow the community rules.
Sign in to join the conversation.
Sign in to comment